MoonLake Immunotherapeutics (MLTX) Debt Ratio (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Debt Ratio of 0.25 for Q1 2026, up 73.16% year-over-year from 0.14 in Q1 2025, and up 41.66% quarter-over-quarter from 0.17 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Debt Ratio (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.25 for Q1 2026.
- In Q1 2026, Debt Ratio rose 73.16% year-over-year to 0.25; the TTM figure through Mar 2026 stood at 0.25 (up 73.16% YoY), while the FY2025 annual figure was 0.17, changed N/A from the prior year.
- Debt Ratio for Q1 2026 stood at 0.25, up from 0.17 in the prior quarter.
- The five-year high for Debt Ratio was 0.25 in Q1 2026, with the low at 0.14 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.12 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.47 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.26 |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 0.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.17 |
| Mar 31, 2026 | 0.25 |
| Dec 31, 2025 | 0.17 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.14 |
| Dec 31, 2021 | 1.55 |